Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
News headline image
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
News headline image
10 Bargain Stocks to Buy After Falling 30% in 2021 ↗
If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill. 
Via InvestorPlace
News headline image
Biotech Playbook 2021: No Help From Small Caps In Q4 ↗
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
News headline image
Adobe Earnings Strangle Trade ↗
Adobe announces earnings this week, and we plan on using an options strategy called a 
Via Talk Markets
News headline image
CRISPR Therapeutics Is One of Today’s Best Biotech Value Investments ↗
Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
News headline image
Why CRISPR Therapeutics Stock Sank 12.5% in November ↗
The gene-editing specialist's share price is now down roughly 54% in 2021. 
Via The Motley Fool
News headline image
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
Via Benzinga
News headline image
Biotech Stocks are Due for a Rally ↗
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
News headline image
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. 
Via The Motley Fool
News headline image
Better Buy: Vertex Pharmaceuticals vs. CRISPR ↗
The companies are collaborating on a potential blockbuster. 
Via The Motley Fool
News headline image
Looking for Growth in Small and Mid Cap Life Science Stocks ↗
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
News headline image
Being First Is Not Enough For Crispr Therapeutics ↗
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
Via InvestorPlace
News headline image
Why CRISPR Therapeutics Stock Fell 18.4% in October ↗
The gene-editing specialist's stock is now down roughly 37% year to date. 
Via The Motley Fool
News headline image
Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics ↗
Vertex plans to develop gene-editing therapies with Mammoth Biosciences. 
Via The Motley Fool
News headline image
3 Things About CRISPR Therapeutics That Smart Investors Know ↗
The company's value isn't reflected in typical performance metrics. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
News headline image
2 Gene-Editing Stocks to Have on Your Radar Right Now ↗
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies. 
Via The Motley Fool
News headline image
2 Top Healthcare Stocks That Could Be Bought Out in 2022 ↗
These two novel-drug makers could be top takeover targets next year. 
Via The Motley Fool
News headline image
If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today ↗
The returns haven't been half bad, to say the least. 
Via The Motley Fool
News headline image
Crispr: A Fallen Angel In Gene Editing ↗
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
News headline image
Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review ↗
It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields. 
Via Investor's Business Daily
News headline image
BZ Chart Of The Day: Is Crisper Therapeutics About To Rally? ↗
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) may be form... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
Via Benzinga
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
News headline image
CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today ↗
Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. 
Via InvestorPlace
News headline image
40 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
Via Benzinga
News headline image
Why CRISPR Therapeutics Stock Is Sinking Today ↗
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Is Tumbling Today ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.